Rubraca (rucaparib) — CareFirst (Caremark)

Initial criteria

• Subsequent treatment of BRCA2‑altered uterine leiomyosarcoma when used as a single agent for advanced, recurrent, metastatic, or inoperable disease

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months